Sfoglia per Autore
Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma
2004 Fanti S.; Yu JQ.; Castellucci P.; Moretti A.; Farsad M.; Nanni C.; Zamagni E.; Cellini C.; Tosi P.; Zhuang HM.; Cavo M.; Baccarani M.; Franchi R.; Salizzoni E.; Canini R.; Monetti N.; Alavi A.
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients.
2004 PICCALUGA PP; MARTINELLI G; RONDONI M; MALAGOLA M; GAITANI S; VISANI G; BACCARANI M.
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia
2004 PICCALUGA PP; LUATTI S; ASCANI S; BIANCHINI M; MALAGOLA M; RONDONI M; GAITANI S; TESTONI N.; PILERI SA; BACCARANI M; MARTINELLI G; VISANI G
Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia.
2004 MANDREOLI M; FINELLI C; LOPEZ A; ASCANI S; VIANELLI N; BACCARANI M.; SANTORO A.
CHK2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571
2004 MAZZACURATI L; PATTACINI L; BRUSA G; MANCINI M; BENVENUTI M; BARBIERI E; MARTINELLI G.; BACCARANI M; GREENBERGER JS; SANTUCCI MA
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly
2004 Piccaluga, Pier Paolo; Martinelli, Giovanni; Rondoni, Michela; Malagola, Michele; Ronconi, Sonia; Visani, Giuseppe; Baccarani, Michele
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas
2004 PICCALUGA PP; MARTINELLI G.; RONDONI M; MALAGOLA M; GAITANI S; ISIDORI A; BONINI A; GUGLIOTTA L; LUPPI M; MORSELLI M; SPARAVENTI G; VISANI G; BACCARANI M.
Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
2004 CILLONI D; MESSA F; GOTTARDI E; FAVA M; ARRUGA F; DEFILIPPI I; CARTURAN S; MESSA E; MOROTTI A; GIUGLIANO E; REGE-CAMBRIN G; ALBERTI D; BACCARANI M.; SAGLIO G.
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP.
2005 Iacobucci, I; Testoni, N; Rosti, G; Amabile, M; Poerio, A; Soverini, S; Colarossi, S; Gnani, A; Ottaviani, E; Castagnetti, F; Terragna, C; Renzulli, M; Grafone, T; Cilloni, D; Pane, F; Saglio, G; Baccarani, M; Martinelli, G
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS).
2005 Lorenzini S.; Isidori A.; Loggi E.;Gramenzi A.; Catani L.; Talarico S.; Cursaro C.; Biselli M.; Bonifazi F.; Lemoli RM.; Baccarani M.; Bernardi M.; Andreone P.
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma.
2005 Tani M; Fina M; Alinari L; Stefoni V; Baccarani M; Zinzani PL.
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.
2005 ZINZANI PL; ALINARI L; TANI M; FINA M; PILERI S; BACCARANI M.
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
2005 Malagola M; Martinelli G; Rondoni M; Paolini S; Gaitani S; Arpinati M; Piccaluga PP; Amabile M; Basi C; Ottaviani E; Candoni A; Gottardi E; Cilloni D; Bocchia M; Saglio G; Lauria F; Fanin R; Visani G; Marre MC; Maderna M; Rancati F; Vinaccia V; Russo D; Baccarani M.
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells.
2005 Curti A.; Pandolfi S.; Aluigi M.; Isidori A.; Alessandrini I.; Chiodoni C.; Testoni N.; Colombo MP.; Baccarani M.; Lemoli RM.
Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma.
2005 RAMBALDI A; CARLOTTI E; OLDANI E; DELLA STARZA I; BACCARANI M.; CORTELAZZO S; LAURIA F; ARCAINI L; MORRA E; PULSONI A; RIGACCI L; RUPOLO M; ZAJA F; ZINZANI PL; BARBUI T; FOA R.
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma.
2005 Marchi E; Alinari L; Tani M; Stefoni V; Pimpinelli N; Berti E; Pagano L; Bernengo MG; Zaja F; Rupoli S; Pileri S; Baccarani M; Zinzani PL
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia
2005 NICCI C; OTTAVIANI E; LUATTI S; GRAFONE T; TONELLI M; MOTTA MR; MALAGOLA M; MARZOCCHI G; MARTINELLI G; BACCARANI M; TESTONI N.
Immune therapy of chronic myelogenous leukemia.
2005 GALE RP; HOROWITZ MM; TALPAZ M; SCHEINBERG DA; MOLLDREM J; LI Z; BACCARANI M.; GOLDMAN JM; TURA S.
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia.
2005 PICCALUGA PP; MARTINELLI G; MALAGOLA M; RONDONI M; BONIFAZI F; BANDINI G; VISANI G; BACCARANI M.
Does early stem-cell transplantation have a role in chronic myeloid leukaemia? Against the proposal.
2005 Rosti G.; Baccarani M.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma | Fanti S.; Yu JQ.; Castellucci P.; Moretti A.; Farsad M.; Nanni C.; Zamagni E.; Cellini C.; Tosi P....; Zhuang HM.; Cavo M.; Baccarani M.; Franchi R.; Salizzoni E.; Canini R.; Monetti N.; Alavi A. | 2004-01-01 | QUARTERLY JOURNAL OF NUCLEAR MEDICINE | - | 4.02 Riassunto (Abstract) | - |
| First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. | PICCALUGA PP; MARTINELLI G; RONDONI M; MALAGOLA M; GAITANI S; VISANI G; BACCARANI M. | 2004-01-01 | LEUKEMIA RESEARCH | - | 1.01 Articolo in rivista | - |
| Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia | PICCALUGA PP; LUATTI S; ASCANI S; BIANCHINI M; MALAGOLA M; RONDONI M; GAITANI S; TESTONI N.; PILE...RI SA; BACCARANI M; MARTINELLI G; VISANI G | 2004-01-01 | CANCER GENETICS AND CYTOGENETICS | - | 1.01 Articolo in rivista | - |
| Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. | MANDREOLI M; FINELLI C; LOPEZ A; ASCANI S; VIANELLI N; BACCARANI M.; SANTORO A. | 2004-01-01 | AMERICAN JOURNAL OF KIDNEY DISEASES | - | 1.01 Articolo in rivista | - |
| CHK2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571 | MAZZACURATI L; PATTACINI L; BRUSA G; MANCINI M; BENVENUTI M; BARBIERI E; MARTINELLI G.; BACCARANI... M; GREENBERGER JS; SANTUCCI MA | 2004-01-01 | HEMATOLOGY JOURNAL | - | 1.01 Articolo in rivista | - |
| Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly | Piccaluga, Pier Paolo; Martinelli, Giovanni; Rondoni, Michela; Malagola, Michele; Ronconi, Sonia;... Visani, Giuseppe; Baccarani, Michele | 2004-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | ECR37.full.pdf |
| Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas | PICCALUGA PP; MARTINELLI G.; RONDONI M; MALAGOLA M; GAITANI S; ISIDORI A; BONINI A; GUGLIOTTA L; ...LUPPI M; MORSELLI M; SPARAVENTI G; VISANI G; BACCARANI M. | 2004-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. | CILLONI D; MESSA F; GOTTARDI E; FAVA M; ARRUGA F; DEFILIPPI I; CARTURAN S; MESSA E; MOROTTI A; GI...UGLIANO E; REGE-CAMBRIN G; ALBERTI D; BACCARANI M.; SAGLIO G. | 2004-01-01 | CANCER | - | 1.01 Articolo in rivista | - |
| Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. | Iacobucci, I; Testoni, N; Rosti, G; Amabile, M; Poerio, A; Soverini, S; Colarossi, S; Gnani, A; O...ttaviani, E; Castagnetti, F; Terragna, C; Renzulli, M; Grafone, T; Cilloni, D; Pane, F; Saglio, G; Baccarani, M; Martinelli, G | 2005-01-01 | - | - | 4.02 Riassunto (Abstract) | - |
| GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS). | Lorenzini S.; Isidori A.; Loggi E.;Gramenzi A.; Catani L.; Talarico S.; Cursaro C.; Biselli M.; B...onifazi F.; Lemoli RM.; Baccarani M.; Bernardi M.; Andreone P. | 2005-01-01 | JOURNAL OF HEPATOLOGY | - | 4.02 Riassunto (Abstract) | - |
| Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. | Tani M; Fina M; Alinari L; Stefoni V; Baccarani M; Zinzani PL. | 2005-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. | ZINZANI PL; ALINARI L; TANI M; FINA M; PILERI S; BACCARANI M. | 2005-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? | Malagola M; Martinelli G; Rondoni M; Paolini S; Gaitani S; Arpinati M; Piccaluga PP; Amabile M; B...asi C; Ottaviani E; Candoni A; Gottardi E; Cilloni D; Bocchia M; Saglio G; Lauria F; Fanin R; Visani G; Marre MC; Maderna M; Rancati F; Vinaccia V; Russo D; Baccarani M. | 2005-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. |
Curti A.; Pandolfi S.; Aluigi M.; Isidori A.; Alessandrini I.; Chiodoni C.; Testoni N.; Colombo ...MP.; Baccarani M.; Lemoli RM. |
2005-01-01 | EXPERIMENTAL HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. | RAMBALDI A; CARLOTTI E; OLDANI E; DELLA STARZA I; BACCARANI M.; CORTELAZZO S; LAURIA F; ARCAINI L...; MORRA E; PULSONI A; RIGACCI L; RUPOLO M; ZAJA F; ZINZANI PL; BARBUI T; FOA R. | 2005-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. |
Marchi E; Alinari L; Tani M; Stefoni V; Pimpinelli N; Berti E; Pagano L; Bernengo MG; Zaja F; Ru...poli S; Pileri S; Baccarani M; Zinzani PL |
2005-01-01 | CANCER | - | 1.01 Articolo in rivista | - |
| Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia | NICCI C; OTTAVIANI E; LUATTI S; GRAFONE T; TONELLI M; MOTTA MR; MALAGOLA M; MARZOCCHI G; MARTINEL...LI G; BACCARANI M; TESTONI N. | 2005-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
| Immune therapy of chronic myelogenous leukemia. | GALE RP; HOROWITZ MM; TALPAZ M; SCHEINBERG DA; MOLLDREM J; LI Z; BACCARANI M.; GOLDMAN JM; TURA S. | 2005-01-01 | LEUKEMIA RESEARCH | - | 1.01 Articolo in rivista | - |
| Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. | PICCALUGA PP; MARTINELLI G; MALAGOLA M; RONDONI M; BONIFAZI F; BANDINI G; VISANI G; BACCARANI M. | 2005-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
| Does early stem-cell transplantation have a role in chronic myeloid leukaemia? Against the proposal. | Rosti G.; Baccarani M. | 2005-01-01 | THE LANCET ONCOLOGY | - | 1.01 Articolo in rivista | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile